Table 1—

Baseline characteristics(safety population)

PlaceboSAL 50 μgFP 500 μgSFC 50 μg/500 μgTotal
Patients n15441542155215466184
Age yrs65±865±865±865±865±8
Sex
 Male1175 (76)1176 (76)1169 (75)1164 (75)4684 (76)
 Female369 (24)366 (24)383 (25)382 (25)1500 (24)
Smoking status
 Former880 (57)885 (57)886 (57)879 (57)3530 (57)
 Current664 (43)657 (43)666 (43)667 (43)2654 (43)
Total pack-yrs49±2749±2949±2747±2749±28
Baseline FEV1#44 (13)44 (13)45 (13)45 (14)44 (13)
Reversibility %10±1110±1110±1110±1110±11
  • Data are presented as mean±sd or n (%), unless otherwise stated. SAL: salmeterol; FP: fluticasone propionate; SFC: SAL plus FP combination; FEV1: forced expiratory volume in 1 s. #: data presented as value (% predicted post-bronchodilator).